A Case of Pantoprazole Anaphylaxis with Cross Reactivity to All Proton Pump Inhibitors: Finding a Safe Alternative

Title:A Case of Pantoprazole Anaphylaxis with Cross Reactivity to All Proton Pump Inhibitors: Finding a Safe Alternative

Volume: 12 Issue: 3

Author(s): Ozlem Turedi, Zeynep Celebi Sozener, Resat Kendirlinan and Sevim Bavbek*

Affiliation:

• Department of Clinical Immunology and Allergy, Ankara University, School of Medicine, Ankara,Turkey

Keywords: Pantoprazole anaphylaxis, cross reactivity, proton pump inhibitors, intradermal tests, H2 receptor, skin prick tests, oral provocation tests, safe alternatives.

Abstract: Background: Hypersensitivity reactions due to Proton pump inhibitors (PPIs ) are rare, and further anaphylaxis to a PPI with cross-reactivity to all commercially available PPIs is very rare.

Objective: To present a case of anaphylaxis to pantoprazole with cross-reactivity to all commercially available PPIs.

Methods: Skin prick tests (SPTs), intradermal tests (IDTs) and oral provocation tests (OPTs) were performed with available PPIs according to the method described in previous studies.

Results: All tested PPIs except lansoprazole were positive on skin tests either SPT or IDT. The patient was challenged with lansoprazole at increasing doses (7.5 mg, 15 mg, 30 mg capsule) every 60 minutes and she reacted with urticaria to 52.5 mg cumulative dose of lansoprazole. She could tolerate ranitidine and famotidine tablets via OPT.

Conclusion: In our best knowledge, our case was the first case in this regard and that points the possibility of all cross-reactive pattern in patients with pantoprazole anaphylaxis and the importance of a thorough drug allergy work-up for finding safe alternatives. H2 receptor antagonists are used as safe alternatives in cases with PPI hypersensitivity.

Cite this article as:

Turedi Ozlem, Sozener Celebi Zeynep , Kendirlinan Resat and Bavbek Sevim *, A Case of Pantoprazole Anaphylaxis with Cross Reactivity to All Proton Pump Inhibitors: Finding a Safe Alternative, Current Drug Safety 2017; 12 (3) . https://dx.doi.org/10.2174/1574886312666170711122341